Validating the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)

被引:33
作者
Bailey, Jayne E. [1 ]
Dawson, Gerard R. [2 ]
Dourish, Colin T. [2 ]
Nutt, David J. [3 ]
机构
[1] Univ Bristol, Sch Med Sci, Severnside Alliance Translat Res, Bristol BS8 1TD, Avon, England
[2] Univ Oxford, Warneford Hosp, Dept Psychiat, P1Vital, Oxford, England
[3] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Neuropsychopharmacol Unit, London, England
关键词
7.5% CO2; anxiety; experimental medicine; generalized anxiety disorder; translational medicine; PLACEBO-CONTROLLED TRIAL; POTENTIATED STARTLE; SLEEP-DEPRIVATION; CARBON-DIOXIDE; DOUBLE-BLIND; STRESS TEST; ASSOCIATION; FEAR; BENZODIAZEPINES; MULTICENTER;
D O I
10.1177/0269881111408455
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Anxiety is a complex phenomenon that can represent contextually different experiences to individuals. The experimental modelling in healthy volunteers of clinical anxiety experienced by patients is challenging. Furthermore, defining when and why anxiety (which is adaptive) becomes an anxiety disorder (and hence maladaptive) is the subject of much of the published literature. Observations from animal studies can be helpful in deriving mechanistic models, but gathering evidence from patients and reverse translating this to healthy volunteers and thence back to laboratory models is a more powerful approach and is likely to more closely model the clinical disorder. Thus the development and validation of a robust healthy volunteer model of anxiety may help to bridge the gap between the laboratory and the clinic and provide 'proof of concept' in screening for novel drug treatments. This review considers these concepts and outlines evidence from a validated healthy volunteer model of generalized anxiety disorder (GAD) following the inhalation of 7.5% CO2.
引用
收藏
页码:1192 / 1198
页数:7
相关论文
共 40 条
[1]   Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder - Twenty-four-week placebo-controlled dose-ranging study [J].
Allgulander, C ;
Hackett, D ;
Salinas, E .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 :15-22
[2]   Benzodiazepines have no effect on fear-potentiated startle in humans [J].
Baas, JMP ;
Grillon, C ;
Böcker, KBE ;
Brack, AA ;
Morgan, CA ;
Kenemans, JL ;
Verbaten, MN .
PSYCHOPHARMACOLOGY, 2002, 161 (03) :233-247
[3]   An Experimental Investigation of the Effects of Acute Sleep Deprivation on Panic-Relevant Biological Challenge Responding [J].
Babson, Kimberly A. ;
Feldner, Matthew T. ;
Trainor, Casey D. ;
Smith, Rose C. .
BEHAVIOR THERAPY, 2009, 40 (03) :239-250
[4]   A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety [J].
Bailey, J. E. ;
Papadopoulos, A. ;
Seddon, K. ;
Nutt, D. J. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2009, 23 (02) :117-122
[5]   GABA-A receptors and the response to CO2 inhalation -: A translational trans-species model of anxiety? [J].
Bailey, Jayne E. ;
Nutt, David J. .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2008, 90 (01) :51-57
[6]   A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers [J].
Bailey, Jayne E. ;
Kendrick, Adrian ;
Diaper, Alison ;
Potokar, John P. ;
Nutt, David J. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2007, 21 (01) :42-49
[7]   Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety [J].
Bailey, Jayne E. ;
Papadopoulos, Andreas ;
Diaper, Alison ;
Phillips, Suzanne ;
Schmidt, M. E. ;
van der Ark, P. ;
Dourish, Colin T. ;
Dawson, Gerard R. ;
Nutt, David J. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (09) :1199-1206
[8]   Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology [J].
Baldwin, DS ;
Anderson, IM ;
Nutt, DJ ;
Bandelow, B ;
Bond, A ;
Davidson, JRT ;
den Boer, JA ;
Fineberg, NA ;
Knapp, M ;
Scott, J ;
Wittchen, HU .
JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (06) :567-596
[9]   Neuroimaging and Genetics of Antidepressant Response to Sleep Deprivation: Implications for Drug Development [J].
Benedetti, Francesco ;
Smeraldi, Enrico .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (22) :2637-2649
[10]   Opportunities and challenges of psychiatric drug discovery: Roles for scientists in academic, industry, and government settings [J].
Conn, P. Jeffrey ;
Roth, Bryan L. .
NEUROPSYCHOPHARMACOLOGY, 2008, 33 (09) :2048-2060